GlassScriptPhysician profile
James D Adamo
NPI 1851311021
$27,703.75
in general payments reported to CMS, 2019-2025
44 companies · $6,082 in 2025
The $6,082 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,877 · 2020: $2,480 · 2021: $2,029 · 2022: $2,405 · 2023: $6,780 · 2024: $5,050 · 2025: $6,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $990 · Education: $28.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,894.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $990.00 |
| Education | $28.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,668.05 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $2,518.01 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,386.55 | 2020-2025 | Caplyta |
| Abbvie INC. | $2,057.42 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $1,966.84 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $1,780.15 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Corium, LLC | $1,482.36 | 2022-2025 | Azstarys |
| Lundbeck LLC | $1,397.97 | 2019-2025 | Rexulti, Vyepti |
| Vanda Pharmaceuticals INC. | $1,098.61 | 2020-2025 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $892.60 | 2019-2022 | |
| Alkermes, INC. | $888.67 | 2020-2025 | Aristada, Lybalvi |
| Tris Pharma INC | $882.49 | 2019-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $789.74 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $746.52 | 2019-2022 | |
| Axsome Therapeutics, INC. | $651.20 | 2023-2025 | Auvelity |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $603.19 | 2022-2025 | Qelbree, Qelbree |
| Validus Pharmaceuticals LLC | $442.30 | 2019-2025 | Equetro, Equetro, Raldesy |
| Sage Therapeutics, LLC | $422.18 | 2024-2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $413.25 | 2022-2024 | Quviviq |
| Almatica Pharma LLC | $408.54 | 2023-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $383.85 | 2025 | Cobenfy |
| Allergan, INC. | $375.07 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $321.12 | 2019-2024 | |
| Bausch Health US, LLC | $309.47 | 2019-2025 | Aplenzin, Wellbutrin |
| Indivior INC. | $304.12 | 2019-2024 | Perseris, Sublocade |
| Collegium Pharmaceutical, INC. | $205.57 | 2025 | Jornay Pm |
| Shire North American Group INC | $196.01 | 2019 | |
| Neos Therapeutics, LP | $191.92 | 2019-2025 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $128.92 | 2020-2023 | Belsomra |
| Eisai INC. | $111.69 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $98.76 | 2020-2021 | |
| Adlon Therapeutics L.P. | $98.08 | 2019-2021 | |
| Luye Pharma (USA) LTD. | $75.57 | 2025 | Erzofri Extended-Release |
| Novo Nordisk INC | $75.35 | 2024-2025 | Wegovy |
| Brainsway USA INC | $73.40 | 2025 | Deep Tms System |
| Owp Pharmaceuticals, INC. | $65.28 | 2019-2025 | Subvenite |
| Bioxcel Therapeutics, INC. | $40.14 | 2023 | Igalmi |
| Lilly USA, LLC | $36.90 | 2025 | Zepbound, Mounjaro |
| Noven Therapeutics, LLC | $23.41 | 2024 | Xelstrym |
| Janssen Biotech, INC. | $22.18 | 2023 | |
| Alfasigma USA, INC. | $21.71 | 2020 | |
| Neuronetics, INC. | $19.66 | 2019-2023 | Neurostar Tms Therapy System |
| Acadia Pharmaceuticals INC | $17.89 | 2020 | |
| Arbor Pharmaceuticals, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Adamo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.